
Sign up to save your podcasts
Or


In this podcast series on pre- and post- COVID-19 prophylaxis, we discuss immunization against COVID-19 and how we can protect our most vulnerable populations who are not able to mount a sufficient antibody response to vaccination.
In this second episode of the series, we discuss:
Our Guest:
Our guest is Dr. Zain Chagla, who is an associate professor at McMaster University, co-medical director of infection control at St. Joseph’s Healthcare Hamilton and a consultant in infection control at Woodstock General Hospital. Dr. Chagla’s research and clinical interests include monoclonal antibody use in COVID-19, infections in renal transplantation, global health and tropical medicine, education and antimicrobial stewardship, and ultrasound in infectious diseases.
This podcast episode was sponsored by AstraZeneca Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
In this podcast series on pre- and post- COVID-19 prophylaxis, we discuss immunization against COVID-19 and how we can protect our most vulnerable populations who are not able to mount a sufficient antibody response to vaccination.
In this first episode of the series, we discuss:
Our Guest:
Our guest is Dr. Brian Conway, who is an infectious diseases specialist and the medical director of the Vancouver Infectious Diseases Centre, dedicated to the development and evaluation of systems of care for inner city vulnerable population. The models his team has established have led to increased access to HIV and HCV care as well as addiction services in a unique and durable manner. He is an adjunct professor in the Faculty of Health Sciences at Simon Fraser University. In 2012, he received the Queen Elizabeth II Diamond Jubilee Medal for long-standing service to the country in the field of HIV. In 2020, the Coalition for Global Hepatitis Elimination recognized Dr. Conway’s group as one of 6 global elimination champions. In the times of COVID-19, he has been sought out by local and national media to help Canadians make sense of the pandemic. Through generous funding from the Public Health Agency of Canada, he is currently involved in optimizing vaccine and treatment understanding and uptake among inner city residents.
This podcast episode was sponsored by AstraZeneca Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
In this episode of IMPACT Medicom’s Precision Medicine in Oncology podcast series, we discuss the evolving biomarker landscape in gastrointestinal malignancies and some of the advantages and challenges of implementing and accessing biomarker testing.
Our guest:
Dr. Rosalyn Juergens is a medical oncologist with clinical expertise in lung and esophageal cancer. She was on the faculty at The Johns Hopkins Medical Institute from 2007-2010 until she joined the faculty at McMaster University in 2011. Dr. Juergens’ leadership roles include serving as chair of the Lung Disease Site Team and Head of the Department of Clinical Trials at the Juravinski Cancer Centre in Hamilton, Ontario. She is also the chair of the Executive Committee of the Canadian Cancer Trials Group Investigational New Drug Committee and Medical Advisory Committee Chair for Lung Cancer Canada. Dr. Juergens’ research interests involve improving therapeutics and diagnostics in cancer, with a focus on developmental therapeutics and Phase I and II clinical trials.
This podcast episode was sponsored by Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Welcome to episode 9 of IMPACT Medicom’s podcast series on Precision Medicine in Oncology, the second episode in a 3-part series on ovarian cancer. This episode, hosted by IMPACT Medicom’s Sarah Doucette, features a debate on whether first-line maintenance therapy with PARP inhibitors can be considered a curative strategy in patients with advanced, BRCA-mutated epithelial ovarian cancer.
Our Guests:
Dr. Taymaa May
Taymaa May is a surgical scientist at the University Health Network and an Associate Professor at the University of Toronto. Dr. May is the surgical oncology lead for Toronto central south, Ontario Health/Cancer Care Ontario and the chair of the Gynecologic Oncology Group of Ontario. She is the director of clinical specialty programs in the department of surgical oncology and a member of the Princess Margaret executive. She is also the current chair of the Gynecologic Oncology of Canada’s (GOC) Annual General Meeting and is a member of GOC’s board of directors. Dr. May’s research focuses on surgical innovation and translational research in ovarian cancer.
Dr. James Bentley
Dr. James Bentley is a Professor and Head of the Department of Obstetrics and Gynaecology at Dalhousie University. He is a Past President of the International Federation of Cervical Pathology and Colposcopy (IFCPC), the Society of Gynaecologic Oncology of Canada (GOC), and the Society of Canadian Colposcopists, and is the past Chair of the Royal College Nucleus Committee for Gynecologic Oncology. He continues to serve on numerous national and provincial committees involved with cervical cancer screening and gynecological cancer. Dr. Bentley's clinical interests lie in the field of cervical cancer prevention, colposcopy, clinical trials including the application of HPV Vaccines and chemotherapy trials.
Links:
SOLO-1 5-year update: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00531-3/fulltext
Correlation between BRCA status and surgical cytoreduction: https://www.gynecologiconcology-online.net/article/S0090-8258(21)00540-0/fulltext
This podcast episode was sponsored by Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Welcome to episode 8 of IMPACT Medicom’s podcast series on Precision Medicine in Oncology, the first in a series of episodes focusing on ovarian cancer. In this episode, we discuss the importance of BRCA testing for patients with advanced epithelial ovarian cancer and how national initiatives have helped to improve BRCA testing standards across the country.
Our Guests:
Dr. Janice Kwon, Gynecologic Oncologist at Vancouver Coastal Health and Vice Head and Professor in the Department of Obstetrics and Gynecology at the University of British Columbia. Dr. Kwon serves as Chair of both the Priority and Evaluations Committee at BC Cancer and the National BRCA Collaborative. Her expertise is in hereditary cancer syndromes and conducting cost-effectiveness analyses of testing criteria and risk-reducing
interventions.
Dr. Alon Altman, Gynecologic Oncologist and Professor at the University of Manitoba, and the Winnipeg Health Sciences Centre/Cancercare Manitoba. Dr. Altman is the president elect for the Society of Gynecologic Oncology of Canada (the GOC). He is actively involved in multiple other university, national and international committees including serving as program director for the department of Obstetrics and Gynecology, chair of the University Medical Group (UMG), vice chair for the Medical Management Safety Committee (MMSC) at CancerCare Manitoba, and Gynecologic oncology track lead for the FIGO 2021 Scientific planning committee.
This podcast episode was sponsored by Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
In this seventh episode of our podcast series on precision medicine, hosted by Anna Christofides, we discuss genomic testing in prostate cancer. Our episode focuses on the evolution and uptake of genetic testing in prostate cancer. We discuss testing for homologous recombination repair (HRR) genes and their association with prognosis and influence on treatment decisions. We also discuss somatic vs germline testing and who is responsible for ordering genomic tests.
Our guest:
Our guest on today’s episode is Dr. Neil Fleshner, who is the Martin Barkin Chair and a Professor of Surgery at the Division of Urology at the University of Toronto in Toronto, Ontario. He is also affiliated with Sunnybrook Hospital, Mount Sinai Hospital, Princess Margaret Cancer Centre (UHN), and the Toronto General Hospital (UHN).
This podcast episode was sponsored by AstraZeneca Canada and Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Welcome to episode 6 of IMPACT Medicom’s podcast series on Precision Medicine in Oncology. In this episode Dr. Gonzalez discusses testing methodology, particularly for mismatch repair deficiency, as well as potential emerging biomarkers for metastatic colorectal cancer.
Our Guest:
Dr. Raul Gonzalez is an Associate Professor of Pathology at Harvard Medical School and the Director of Gastrointestinal Pathology at Beth Israel Deaconess Medical Center in Boston, Massachusetts. Dr. Gonzalez is a surgical pathologist specializing in gastrointestinal pathology. He is the Editor- in-Chief of Pathology Outlines and the Reviews Editor for Histopathology. He also serves as the Vice Chair for the College of American Pathologists Surgical Pathology Committee and the Website Committee Chair for the Hans Popper Hepatopathology Society.
This podcast episode was sponsored by Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
In this episode of our podcast, we discuss the use of zanubrutinib for the treatment of Waldenstrom’s Macroglobulinemia. Our episode discusses data from the Phase 3 ASPEN trial, comparing the efficacy and safety of zanubrutinib with ibrutinib in these patients.
Our Guests
Our first guest, Dr. Constantine Tam, is a Professor of Hematology at the University of Melbourne, and Consultant Hematologist at the Peter MacCallum Cancer Centre in Melbourne, Australia. He is also the lead author on the ASPEN trial, and provides a detailed look at the key data from this study.
We are then joined by Dr. Carolyn Owen, an Associate Professor in the Division of Hematology & Hematological Malignancies at the University of Calgary. Dr. Owen discusses the potential impact of the data from the ASPEN trial on Canadian clinical practice. And how zanubrutinib may fit into the Canadian treatment algorithm for Waldenstrom’s Macroglobulinemia.
This podcast episode was sponsored by Beigene Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
In this episode of IMPACT Medicom’s podcast series on Precision Medicine in Oncology we discuss:
· The current standards for molecular testing in metastatic colorectal cancer
· The potential benefit of a Canadian guideline for molecular testing in metastatic colorectal cancer
Our guest:
Dr. Sharlene Gill is Professor of Medicine at the University of British Columbia and Medical Oncologist at BC Cancer in Vancouver. Dr. Gill earned her MD from the University of British Columbia and completed a fellowship in gastrointestinal oncology at the Mayo Clinic (Rochester, MN). She also received a Master of Public Health degree from the Harvard School of Public Health and completed her MBA at the Kenan-Flagler School of Business at the University of North Carolina. Dr. Gill currently specializes in the treatment of gastrointestinal malignancies and serves as the Chair of the Canadian Clinical Trials Group GI Disease Site Committee. In addition, she is President-Elect of the Canadian Association of Medical Oncologists and is Editor-in-Chief for the peer-reviewed journal Current Oncology.
This podcast episode was sponsored by Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Background
Our Guests
Dr. Donna Maziak: Thoracic surgeon and surgical oncologist at the Ottawa Hospital, Ottawa, Ontario.
Chantal Bornais: Nurse navigator at the Ottawa Hospital, Ottawa, Ontario.
Resources
Lakeridge Health in Oshawa: https://www.lakeridgehealth.on.ca/en/central-east-regional-cancer-program/lung-cancer-screening-pilot.asp
TO FIND A SCREENING PROGRAM NEAR YOU: https://right2survive.ca/resource-centre/screening/
If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.